全文获取类型
收费全文 | 46901篇 |
免费 | 4431篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 611篇 |
儿科学 | 1245篇 |
妇产科学 | 1316篇 |
基础医学 | 6804篇 |
口腔科学 | 1250篇 |
临床医学 | 5760篇 |
内科学 | 8184篇 |
皮肤病学 | 594篇 |
神经病学 | 3779篇 |
特种医学 | 2054篇 |
外国民族医学 | 1篇 |
外科学 | 6143篇 |
综合类 | 864篇 |
一般理论 | 23篇 |
预防医学 | 5238篇 |
眼科学 | 1086篇 |
药学 | 3535篇 |
2篇 | |
中国医学 | 68篇 |
肿瘤学 | 2844篇 |
出版年
2021年 | 650篇 |
2019年 | 639篇 |
2018年 | 745篇 |
2017年 | 625篇 |
2016年 | 609篇 |
2015年 | 702篇 |
2014年 | 939篇 |
2013年 | 1459篇 |
2012年 | 2137篇 |
2011年 | 2220篇 |
2010年 | 1187篇 |
2009年 | 980篇 |
2008年 | 1859篇 |
2007年 | 2009篇 |
2006年 | 2005篇 |
2005年 | 2002篇 |
2004年 | 1817篇 |
2003年 | 1667篇 |
2002年 | 1702篇 |
2001年 | 1598篇 |
2000年 | 1705篇 |
1999年 | 1438篇 |
1998年 | 619篇 |
1997年 | 492篇 |
1996年 | 497篇 |
1995年 | 508篇 |
1994年 | 426篇 |
1993年 | 436篇 |
1992年 | 1253篇 |
1991年 | 1161篇 |
1990年 | 1145篇 |
1989年 | 1065篇 |
1988年 | 983篇 |
1987年 | 987篇 |
1986年 | 908篇 |
1985年 | 906篇 |
1984年 | 708篇 |
1983年 | 622篇 |
1982年 | 438篇 |
1981年 | 385篇 |
1980年 | 397篇 |
1979年 | 655篇 |
1978年 | 519篇 |
1977年 | 409篇 |
1976年 | 399篇 |
1975年 | 372篇 |
1974年 | 451篇 |
1973年 | 438篇 |
1972年 | 450篇 |
1971年 | 423篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
Shylo R. Johnson Dennis Slate Kathleen M. Nelson Amy J. Davis Samual A. Mills John T. Forbes Kurt C. VerCauteren Amy T. Gilbert Richard B. Chipman 《Viruses》2021,13(2)
Since the 1990s, oral rabies vaccination (ORV) has been used successfully to halt the westward spread of the raccoon rabies virus (RV) variant from the eastern continental USA. Elimination of raccoon RV from the eastern USA has proven challenging across targeted raccoon (Procyon lotor) and striped skunk (Mephitis mephitis) populations impacted by raccoon RV. Field trial evaluations of the Ontario Rabies Vaccine Bait (ONRAB) were initiated to expand ORV products available to meet the rabies management goal of raccoon RV elimination. This study describes the continuation of a 2011 trial in West Virginia. Our objective was to evaluate raccoon and skunk response to ORV occurring in West Virginia for an additional two years (2012–2013) at 75 baits/km2 followed by three years (2014–2016) of evaluation at 300 baits/km2. We measured the change in rabies virus-neutralizing antibody (RVNA) seroprevalence in targeted wildlife populations by comparing levels pre- and post-ORV during each year of study. The increase in bait density from 75/km2 to 300/km2 corresponded to an increase in average post-ORV seroprevalence for raccoon and skunk populations. Raccoon population RVNA levels increased from 53% (300/565, 95% CI: 50–57%) to 82.0% (596/727, 95% CI: 79–85%) during this study, and skunk population RVNA levels increased from 11% (8/72, 95% CI: 6–20%) to 39% (51/130, 95% CI: 31–48%). The RVNA seroprevalence pre-ORV demonstrated an increasing trend across study years for both bait densities and species, indicating that multiple years of ORV may be necessary to achieve and maintain RVNA seroprevalence in target wildlife populations for the control and elimination of raccoon RV in the eastern USA. 相似文献
14.
15.
16.
Susan C. Fox Jane A. May Natalia Dovlatova Jackie R. Glenn Andrew Johnson Ann E. White 《Platelets》2019,30(3):290-295
Measurement of P-selectin on activated platelets as a means of measuring platelet function utilizing the technology described here has the advantage of not requiring immediate access to specialist equipment and expertise. Blood samples are activated, fixed, stored, and transported to a central laboratory for flow cytometric analysis. Here we have compared P-selectin with other more traditional approaches to measuring platelet function in blood and/or platelet-rich plasma (PRP) from patients with acute coronary syndromes on treatment for at least 1 month with either aspirin and clopidogrel or aspirin with prasugrel. The comparators were light transmission aggregometry (LTA), VerifyNow and Multiplate aggregometry (for determining the effects of aspirin) and LTA, VerifyNow and Multiplate together with the BioCytex VASP phosphorylation assay (for the P2Y12 antagonists). The P-selectin Aspirin Test revealed substantial inhibition of platelet function in all but three of 96 patients receiving aspirin with clopidogrel and in none of 51 patients receiving aspirin and prasugrel. The results were very similar to those obtained using LTA. There was only one patient with high residual platelet aggregation and low P-selectin expression. The same patients identified as “non-responders” to aspirin also presented with the highest residual platelet activity as measured using the VerifyNow system, although not quite as well separated from the other values. With the Multiplate test only one of these patients clearly stood out from the others. The results obtained using the P-selectin P2Y12 Test in 102 patients taking aspirin and clopidogrel were similar to the more traditional approaches in that a wide scatter of results was obtained. Generally, high values seen with the P-selectin P2Y12 Test were also high with the LTA, VerifyNow, Multiplate, and BioCytex VASP P2Y12 Tests. Similarly, low residual platelet function using the P2Y12 test was seen irrespective of the testing procedure used. However, there were differences in some patients. Prasugrel was always more effective than clopidogrel in inhibiting platelet function with none of 56 patients (P-selectin and VerifyNow), only 2 of 56 patients (Multiplate) and only 3 of 56 patients (Biocytex VASP) demonstrating high on-treatment residual platelet reactivity (HRPR) defined using previously published cut-off values. The exception was LTA where there were 11 of 56 patients with HRPR. It remains to be seen which experimental approach provides the most useful information regarding outcomes after adjusting therapies in treated patients. 相似文献
17.
18.
19.
20.